What the FDA labels say about taking them together
Rolapitant and topotecan
Rolapitant's FDA label of August 19, 2020 names topotecan in its drug interactions section; the topotecan labels PlainMeds reads (3) do not name rolapitant. The rolapitant label: “Increased plasma concentrations of BCRP substrates may result in potential adverse reactions.”
Check it at the source: the rolapitant FDA label on DailyMed (effective August 19, 2020, TerSera Therapeutics LLC); the topotecan FDA label on DailyMed (effective July 7, 2022, Novartis Pharmaceuticals Corporation).
What does the rolapitant label say about topotecan?
Rolapitant label, drug interactionsClinical Impact: Increased plasma concentrations of BCRP substrates (…) may result in potential adverse reactions. Intervention: Monitor for adverse reactions related to the concomitant drug if use of VARUBI cannot be avoided. Use the lowest effective dose of rosuvastatin (see prescribing information for additional information on recommended dosing).
Source: FDA drug label (Varubi), TerSera Therapeutics LLC, effective August 19, 2020 (SPL set a52896cd-4a98-49b8-82db-bf1985a64d97), via openFDA; the full label on DailyMed
What does the topotecan label say about rolapitant?
Topotecan's label (effective July 7, 2022) and its 2 other brand-application labels do not name rolapitant in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (HYCAMTIN), NDA020671 (Sandoz), as published by Novartis Pharmaceuticals Corporation, effective July 7, 2022 (SPL set eeee060c-a9ec-423e-a374-8484009f8524), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rolapitant | Topotecan | |
|---|---|---|
| Labeled for | n/a | Lung cancer |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once